Treatment patterns and humanistic burden of malignant pleural mesothelioma in Spain.
Health-related quality of life
Malignant pleural mesothelioma
Spain
Treatment
Journal
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119
Informations de publication
Date de publication:
06 Jul 2024
06 Jul 2024
Historique:
received:
16
05
2024
accepted:
30
06
2024
medline:
6
7
2024
pubmed:
6
7
2024
entrez:
6
7
2024
Statut:
aheadofprint
Résumé
Malignant pleural mesothelioma (MPM) is an aggressive cancer with long latency and poor prognosis. The real-world treatment patterns and humanistic burden of MPM in an international cohort of patients were recently published. Spanish data are currently lacking and are reported here. Data were collected from three sources: physician-abstracted demographic, clinical and treatment characteristics of patients with MPM; patient-completed questionnaires on treatment satisfaction, symptoms, caregiver use, and impact of the disease; and caregiver-completed questionnaire reporting their activity and its impact on their daily life. The 241 patients in Spain were primarily elderly (median age: 67 years), male, retired/unemployed/on long-term sick leave, and diagnosed at stage IV with unresectable disease. Exposure to asbestos was detected (54%, 101/188). First-line treatment (1L) consisted primarily of doublet chemotherapy (86%, 207/241). Of 102 patients who completed 1L at data abstraction, 67 were receiving maintenance therapy, most commonly singlet chemotherapy with pemetrexed. Best supportive care was given to 29 patients, primarily after 1L (86.2%, 25/29). Symptom burden was high and health-related quality of life was poor and declined with progression: mean (SD) EQ-5D score and EQ-5D visual analogue scale score were 0.615 (0.285) and 60.8 (17.1) in 1L and 0.497 (0.370) and 56.1 (19.5) in second line. Overall, 67% of patients (162/241) required daily assistance from their caregiver, who reported an impact on their psychological well-being. Patients with MPM in Spain were overall treated according to treatment guidelines at the time. Nevertheless, a considerable burden of disease was reported by patients and caregivers.
Identifiants
pubmed: 38970770
doi: 10.1007/s12094-024-03591-5
pii: 10.1007/s12094-024-03591-5
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Fels Elliott DR, Jones KD. Diagnosis of mesothelioma. Surg Pathol Clin. 2020;13:73–89.
doi: 10.1016/j.path.2019.10.001
pubmed: 32005436
Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207–18.
doi: 10.1056/NEJMra1912719
pubmed: 34551230
Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.
doi: 10.1097/JTO.0b013e31826915f1
pubmed: 23070243
National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics. 2023. https://seer.cancer.gov/statistics-network/explorer/application.html . Accessed 8 Oct 2023.
Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18:792–802.
doi: 10.1016/j.jtho.2023.01.095
pubmed: 36775192
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. In: Global Cancer Observatory. 2020. https://gco.iarc.fr/today . Accessed 8 Oct 2023.
Meyerhoff RR, Yang CFJ, Speicher PJ, Gulack BC, Hartwig MG, D’Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196:23–32.
doi: 10.1016/j.jss.2015.01.043
pubmed: 25791825
pmcid: 4430361
Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, et al. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Sci Rep. 2021;11:21357.
doi: 10.1038/s41598-021-00831-4
pubmed: 34725384
pmcid: 8560806
Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636–44.
doi: 10.1200/JCO.2003.11.136
pubmed: 12860938
Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute. J Clin Oncol. 2005;23:6881–9.
doi: 10.1200/JCO.20005.14.589
pubmed: 16192580
Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375–86.
doi: 10.1016/S0140-6736(20)32714-8
pubmed: 33485464
OPDIVO® (nivolumab) [package insert]. Princeton NJ:Bristol-Myers Squibb Company; 2023.
OPDIVO® (nivolumab). European Medicines Agency SmPC. Dublin, Ireland:Bristol-Myers Squibb Pharma EEIG; 2023.
Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:2295–306.
doi: 10.1016/S0140-6736(23)01613-6
pubmed: 37931632
Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2022;33:129–42.
doi: 10.1016/j.annonc.2021.11.005
pubmed: 34861373
Mercadante S, Degiovanni D, Casuccio A. Symptom burden in mesothelioma patients admitted to home palliative care. Curr Med Res Opin. 2016;32:1985–8.
doi: 10.1080/03007995.2016.1226165
pubmed: 27532369
Granieri A, Tamburello S, Tamburello A, Casale S, Cont C, Guglielmucci F, et al. Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers. Neuropsychiatr Dis Treat. 2013;9:1193–202.
pubmed: 23983468
pmcid: 3748052
Guerra-Martín MD, Casado-Espinosa MDR, Gavira-López Y, Holgado-Castro C, López-Latorre I, Borrallo-Riego Á. Quality of life in caregivers of cancer patients: a literature review. Int J Environ Res Public Health. 2023;20:1570.
doi: 10.3390/ijerph20021570
pubmed: 36674325
pmcid: 9863368
Moore A, Bennett B, Taylor-Stokes G, Daumont MJ. Caregivers of patients with malignant pleural mesothelioma: who provides care, what care do they provide and what burden do they experience? Qual Life Res. 2023;32:2587–99.
doi: 10.1007/s11136-023-03410-4
pubmed: 37097405
pmcid: 10393857
Moore A, Bennett B, Taylor-Stokes G, McDonald L, Daumont MJ. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe. BMC Cancer. 2022;22:693.
doi: 10.1186/s12885-022-09750-7
pubmed: 35739480
pmcid: 9229520
Szende A, Janssen B, Cabasés J. Self-reported population health: an international perspective based on EQ-5D. Springer Open. 2014.
Remon J, Nadal E, Dómine M, Ruffinelli J, García Y, Pardo JC, et al. Malignant pleural mesothelioma: treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020;147:83–90.
doi: 10.1016/j.lungcan.2020.06.034
pubmed: 32682189
Chu QS, Piccirillo MC, Greillier L, Grosso F, Lo Russo G, Florescu M, et al. IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and IFCT trial. J Clin Oncol. 2023;41:LBA8505.
doi: 10.1200/JCO.2023.41.17_suppl.LBA8505
Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22:1530–40.
doi: 10.1016/S1470-2045(21)00471-X
pubmed: 34656227
pmcid: 8560642
Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405–14.
doi: 10.1016/S0140-6736(15)01238-6
pubmed: 26719230